OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 3, 1998, Pages 860-867

  Yamamura, Yoshitaka ^a   Nakamura, Shigeki ^a   Itoh, Shuji ^a   Hirano, Takahiro ^a   Onogawa, Toshiyuki ^a   Yamashita, Tatsuya ^a   Yamada, Yoshihisa ^a   Tsujimae, Kenji ^a   Aoyama, Masashi ^a   Kotosai, Kounori ^a   Ogawa, Hidenori ^a   Yamashita, Hiroshi ^a   Kondo, Kazumi ^a   Tominaga, Michiaki ^a   Tsujimoto, Gozoh ^a   Mori, Toyoki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BENZAZEPINE DERIVATIVE; CREATININE; DIURETIC AGENT; MOZAVAPTAN; SODIUM; TOLVAPTAN; VASOPRESSIN RECEPTOR; 7 CHLORO 5 HYDROXY 1 [2 METHYL 4 (2 METHYLBENZOYLAMINO)BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPINE; CYCLIC AMP; NITROGEN; UNCLASSIFIED DRUG; UREA; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANIMAL; ARTICLE; BLOOD; DOSE RESPONSE; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HELA CELL; HUMAN; MALE; OSMOLARITY; RAT; SPRAGUE DAWLEY RAT; UREA NITROGEN BLOOD LEVEL; URINE; ANIMAL TISSUE; CONTROLLED STUDY; DRUG EFFECT; HEMOCONCENTRATION; HUMAN CELL; LIGAND BINDING; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING;

ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; BLOOD UREA NITROGEN; CREATININE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MALE; OSMOLAR CONCENTRATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SODIUM; TRANSFECTION;

EID: 0032240078     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL and Kinter LB (1989) Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs. J Pharmacol Exp Ther 249:366-371.
2. Allison NL, Albrightson-Winslow CR, Brooks DP, Stassen FL, Huffman WF, Stote RM and Kinter LB (1988) Species heterogeneity and antidiuretic hormone antagonists: what are the predictors? in Vasopressin: Cellular and Integrative Functions (Cowley AW, Liard JF and Ausiello DA (eds) pp 207-214, Raven Press Ltd., New York.
3. Barter FC and Schwartz WB (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42:790-806.
4. Bichet DG, Szatalowicz V, Chalmovitz C and Schrier RW (1982) Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96:413-417.
5. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brade P and Rosenthal W (1992) Molecular cloning of the receptor for human antidiuretic hormone. Nature 357:333-335.
6. Brooks DP, Koster PF. Albrightson-Winslow CR, Stassen FL, Huffman WF and Kinter LB (1988) SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaco mulatto). J Pharmacol Exp Ther 245:211-215.
7. Cas LD, Metra M and Leier CV (1995) Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. Clin Cardiol 18:370-376.
8. Cheng Y and PrusoffW (1973) Relationship between the inhibition constant (Kj) ami the concentration of inhibition which cause 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. De Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X and Clauser E (1994) Cloning and characterization of the human V3 pituitary vasopressin receptor. FEES Lett 356:215-220.
10. Freidinger RM and Pettibone DJ (1997) Small molecular ligands for oxytoxin and vasopressin receptors Med Res Rev 17:1-16.
11. Goldsmith SR, Francis GS, Cowley AW, Levine TB and Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385-1390.
12. Hawley-Nelson P, Ciccarone V, Gebeyebu G and Jessee J (1989) Lipofectamine™ reagent: a new, higher efficiency polycationic liposome transfection reagent. Gene 77:73-79.
13. Hirasawa A, Shibata K, Kotosai K and Tsujimoto G (1994) Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopres - sin receptor. Biochem Biophys Res Commun 205:1702-1706.
14. Hofbauer KG, Mäh SC and Opperman JR (1986) Chronic blockade of vasopressir receptors in rats. J Cardiovasc Pharmacol 8:S56-S60.
15. Hothorn LA and Lehmacher W (1991) A simple testing procedure "control versus treatment" for one-sided ordered alternatives with application in toxicology. Biom J 33:179-189.
16. Kahn T, Kaufman AM and Mac-Moune FL (1983) Response to repeated frosemide administration on low chloride and low sodium intake in the rat. Clin Sei 64:565-572.
17. Laszlo FA, Laszlo F and DeWied D (1991) Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43:73-108.
18. Lee WH and Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73:257-267.
19. Liu JJ, Phillips PA, Burrell LM, Buxton BB and Johnston CI (1994) Human internal mammary artery responses to non-peptide vasopressin antagonists. Clin Exp Pharmacol Physiol 21:121-124.
20. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A and Brownstein MJ (1992) Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357:336-339.
21. Mah SC and Hofbauer KG (1988) Evaluation of the pharmacologie properties of a vasopressin antagonist in Brattleboro rats. J Pharmacol Exp Ther 245:1028-1032.
22. Mah SC, Opperman JR, Baum HP and Hofbauer KG (1988) Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats. J Pharmacol Exp Ther 245:1021-1027.
23. Manning M and Sawyer WH (1989) Discovery, development and some uses of vasopressin and oxytocin antagonist. J Lab Clin Med 114:617-632.
24. Marcus R, Peritz E and Gabriel KR (1976) On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63:655-660.
25. Michell RH, Kirk CJ and Billah MM (1979) Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7:861-865.
26. Morel A, O'Carroll A, Brownstein MJ and Lolait SJ (1992) Molecular cloning and expression of a rat Vla arginine vasopressin receptor. Nature 356:523-526.
27. Pettibone DJ, Kishel TM, Woyden CJ, Clineschmidt BV, Bock MG, Freidenberg RM, Veber DF and Willianis PD (1992) Radioligand binding studies reveal marked species differences in the vasopressin Vj receptor of rat, rhesus and human tissues. Life Sei 50:1953-1958.
28. Reid IA, Schwartz J, Ben L, Maselli J and Keil LC (1983) Interaction between vasopressin and the renin-angiotensin system. Prog Brain Res 60:475-491.
29. Schrier RW and Niederberger M (1993) Paradoxes of body fluid volume regulation in health and disease: a unifying hypothesis. West J Med 164:393-408.
30. Serradeil-Le Gal C, Wagnon J, Garcia G, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, Guillon G, Cantau B, Barberis C, Trueba M, Ala Y and Jard S (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin Vla receptors. J Clin Invest 92:224-231.
31. Serradeil-Le Gal, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guilon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP and Le Fur G (1996) Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98:2729-2738.
32. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S and Kawashima H (1994) Molecular cloning and functional expression of a cDNA encoding the human Vlb vasopressin receptor. J Biol Chem 269:27088-27092.
33. Szatalowicz VL, Arnold PE, Chalmovitz C, Eichet DG, Berl T and Schrier RW (1981) Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engt J Med 305:263-266.
34. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Takanashi M, Yatsu T, Uchida W and Tanaka A (1997) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin Vla and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282:301-308.
35. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L and Clauser E ( 1994) Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V,a vasopressin receptor. J Biol Chem 269:3304-3310.
36. Verbalis JG (1993) Hypothesis: Epidemiology, pathophysiology, and therapy. Curr Opinion Nephrol Hypertens 2:636-652.
37. Walter SJ and Shirley DG (1986) The effects of chronic hydrochlorothiazide administration on renal function in the rat. Clin Sei 70:379-387.
38. Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M and Yabuuchi Y (1991) OPC-21268, an orally effective, nonpeptide vasopressin V: receptor antagonist. Science 252:572-574.
39. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, Tominaga M and Yabuuchi Y (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105: 787-791.
40. Zerbe R, Stropes L and Robertson G (1980) Vasopressin function in the syndrome of inappropriate antidiuresis. Ann Rev Med 31:315-327.